02999: Evaluating Magnetic Resonance Imaging for Quantifying Histotripsy Ablation in Canine Osteosarcoma

Grant Status: Open

Grant Amount: $25,380
Joanne Tuohy, DVM, PhD; Virginia-Maryland Regional College of Veterinary Medicine
March 1, 2022 - February 28, 2023

Sponsor(s): Golden Retriever FoundationĀ®

Breed(s): Scottish Deerhound, Irish Wolfhound, Greyhound, -All Dogs, Rottweiler
Research Program Area: Oncology - Osteosarcoma
Donate to Support this Research Program Area

One Health: Yes

Abstract

Osteosarcoma (OS) is a devastating and common cancer in dogs. Large and giant breed dogs are predisposed to OS with Scottish Deerhounds, Rottweilers, Irish Wolfhounds, and Greyhounds associated with increased incidence of OS due to genetic factors contributing to increased risk inheritance in these breeds. Current standard-of-care treatment of canine OS involves resection of the primary tumor either via limb amputation or limb-salvage surgery, followed by adjuvant chemotherapy to delay metastatic disease. Limb salvage surgery is associated with high complication rates and not all dogs are appropriate candidates for limb amputation. Despite various permutations in chemotherapeutic regimens, the median survival for canine OS remains at 10-12 months and improved treatment options are needed. Histotripsy is a precision non-thermal focused ultrasound method that mechanically disintegrates tissues. Histotripsy can also potentially induce immune activation towards an anti-tumor immune response. These properties translate into a unique and exciting potential for histotripsy to be an effective non-surgical limb salvage treatment for the primary tumor, and serve as an immunotherapeutic capable of inducing an anti-OS immune response against metastatic disease to increase survival. With CHF-funding (grant #02773), the investigators have acquired data suggesting immune activation in response to histotripsy ablation of canine OS. Complete ablation of OS lesions using histotripsy can achieve non-surgical limb salvage and also potentially stimulate an anti-tumor immune response against metastatic disease. Thus histotripsy is uniquely poised to accomplish the ultimate goal of OS therapy – to target both the primary tumor and metastatic development. Accurately quantifying the degree of histotripsy ablation to confirm complete OS ablation is critical to the success of histotripsy. This study will evaluate the use of magnetic resonance imaging (MRI) to quantify the degree of histotripsy ablation in canine OS and represents a vital step towards translating histotripsy into clinical use as a standard-of-care therapy for dogs with OS.

Publication(s)

None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617
(888)-682-9696

Tax ID# 13-3813813

   2020 GuideStar logo

Ā© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.